Status:
UNKNOWN
Garlic in Patients With Febrile Neutropenia
Lead Sponsor:
Hadassah Medical Organization
Conditions:
Chemotherapy
Neutropenia
Eligibility:
All Genders
16+ years
Phase:
PHASE1
PHASE2
Brief Summary
To determine the clinical effects of garlic in preventing and treatment of patients with chemotherapy related febrile neutropenia.These patients have a very high incidence of infections which are not ...
Detailed Description
Patients eligible are randomized to receive placebo or garlic capsules after chemotherapy course and until leukocyte recovery.
Eligibility Criteria
Inclusion
- FN patients expected to have at least 5 days or more of neutropenia will be eligible for treatment with garlic compounds AST/ALT ≤ 3 times the upper limit of institutional laboratory normal.
- Total bilirubin ≤ 2 times the upper limit of institutional laboratory normal.
- BUN and creatinine should be ≤ 3 times the upper limit of institutional laboratory normal.
- Newly diagnosed as well as previously treated patients will be eligible.
Exclusion
- History of clinically significant liver or kidney disease.
- Patients on anti-coagulation therapy with Coumadin will be excluded because of the potential garlic interference with metabolism.
- Patients receiving concomitant chemotherapeutic treatment
Key Trial Info
Start Date :
June 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2013
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT00247039
Start Date
June 1 2006
End Date
August 1 2013
Last Update
July 8 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hadassah Medical Organization
Jerusalem, Israel